AcelRx Pharmaceuticals Inc (ACRX)-医療機器分野:企業M&A・提携分析

◆英語タイトル:AcelRx Pharmaceuticals Inc (ACRX) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA8013830
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:39
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
AcelRx Pharmaceuticals Inc (AcelRx), is a specialty pharmaceutical company that develops and commercializes novel therapies for the treatment of pain. The company’s lead product candidate, DSUVIA (known as ARX-04 outside the US), is a single sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. It pipeline also includes ZALVISO, a drug and device combination product for management of moderate to severe acute pain in adults. AcelRx incorporates non-invasive, sublingual formulation technology to deliver highly drugs of its product candidates. The company commercializes ZALVISO under license agreement with Grunenthal in the European Union countries, Switzerland, Liechtenstein, Iceland, Norway, and Australia. AcelRx is headquartered in Redwood City, California, the US.

AcelRx Pharmaceuticals Inc (ACRX) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
AcelRx Pharmaceuticals Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 5
AcelRx Pharmaceuticals Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 6
AcelRx Pharmaceuticals Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 7
AcelRx Pharmaceuticals Inc, Medical Equipment, Deals By Market, 2011 to YTD 2017 8
AcelRx Pharmaceuticals Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 9
AcelRx Pharmaceuticals Inc, Medical Equipment, Deal Details 10
Partnerships 10
AcelRx Pharma Amends Commercialization Agreement With Grunenthal For Zalviso 10
Equity Offering 11
AcelRx Pharma Completes Public Offering Of Shares For US$51 Million 11
AcelRx Pharma Completes Underwriters’ Exercise Of Over-Allotment Option For US$6 Million 13
AcelRx Pharma Completes Private Placement Of Units For US$10 Million 15
AcelRx Pharma Completes IPO Of US$40 Million 16
Asset Transactions 18
PDL BioPharma Acquires Portion of Zalviso Royalty Rights from AcelRx Pharma for USD65 Million 18
AcelRx Pharmaceuticals Inc – Key Competitors 20
AcelRx Pharmaceuticals Inc – Key Employees 21
AcelRx Pharmaceuticals Inc – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Financial Announcements 23
Nov 09, 2017: AcelRx Pharmaceuticals Reports Third Quarter 2017 Financial Results 23
Aug 01, 2017: AcelRx Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update 24
May 08, 2017: AcelRx Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update 26
Mar 02, 2017: AcelRx Pharmaceuticals Reports Fourth Quarter and Year End 2016 Financial Results 28
Nov 01, 2016: AcelRx Pharmaceuticals Provides Corporate Update and Reports Third Quarter and Nine Months 2016 Financial Results 30
Jul 28, 2016: AcelRx Pharmaceuticals Provides Corporate Update and Reports Second Quarter and Six Months 2016 Financial Results 32
Mar 07, 2016: AcelRx Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2015 Financial Results 34
Corporate Communications 36
Jul 19, 2017: AcelRx Pharmaceuticals Appoints Raffi Asadorian as Chief Financial Officer 36
Feb 16, 2017: AcelRx Pharmaceuticals Appoints Vincent J. Angotti Chief Executive Officer 37
Mar 29, 2016: AcelRx Pharmaceuticals Names Howard B. Rosen as Chief Executive Officer and Provides Update on Clinical Development Activities and Corporate Priorities for 2016 38
Appendix 39
Methodology 39
About GlobalData 39
Contact Us 39
Disclaimer 39

List of Tables
AcelRx Pharmaceuticals Inc, Medical Equipment, Key Facts, 2016 2
AcelRx Pharmaceuticals Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
AcelRx Pharmaceuticals Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 5
AcelRx Pharmaceuticals Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 6
AcelRx Pharmaceuticals Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 7
AcelRx Pharmaceuticals Inc, Deals By Market, 2011 to YTD 2017 8
AcelRx Pharmaceuticals Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 9
AcelRx Pharma Amends Commercialization Agreement With Grunenthal For Zalviso 10
AcelRx Pharma Completes Public Offering Of Shares For US$51 Million 11
AcelRx Pharma Completes Underwriters' Exercise Of Over-Allotment Option For US$6 Million 13
AcelRx Pharma Completes Private Placement Of Units For US$10 Million 15
AcelRx Pharma Completes IPO Of US$40 Million 16
PDL BioPharma Acquires Portion of Zalviso Royalty Rights from AcelRx Pharma for USD65 Million 18
AcelRx Pharmaceuticals Inc, Key Competitors 20
AcelRx Pharmaceuticals Inc, Key Employees 21
AcelRx Pharmaceuticals Inc, Subsidiaries 22

★海外企業調査レポート[AcelRx Pharmaceuticals Inc (ACRX)-医療機器分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Claris Lifesciences Ltd (533288)-製薬・医療分野:企業M&A・提携分析
    Summary Claris Lifesciences Ltd (Claris) is a manufacturer of generic drugs and pharmaceutical products. The company offers generic drugs that are directly injected into the human body, which is mainly used in the treatment of critical illnesses. Its products are offered through various delivery sys …
  • Occidental Petroleum Corp (OXY):企業の財務・戦略的SWOT分析
    Occidental Petroleum Corp (OXY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • CellSeed Inc (7776):企業の製品パイプライン分析
    Summary CellSeed Inc (CellSeed) is a developer of regenerative medicine. The company’s products include epithelial cell sheet for corneal regeneration, regenerated cardiac patch, epithelial cell sheet for esophageal regeneration, cell sheet for periodontal tissue regeneration and regenerated cartila …
  • Sejal Glass Limited (SEZAL):企業の財務・戦略的SWOT分析
    Sejal Glass Limited (SEZAL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Carmanah Technologies Corporation:企業の戦略的SWOT分析
    Carmanah Technologies Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • OmniComm Systems Inc (OMCM):医療機器:M&Aディール及び事業提携情報
    Summary OmniComm Systems Inc (OmniComm) is a provider of electronic data capture and eClinical software and services. It provides web-based applications to pharmaceutical, biotech and medical device companies. The company’s solutions allow clinical trial sponsors and investigative sites to securely …
  • Ciber, Inc.:企業の戦略・SWOT・財務情報
    Ciber, Inc. - Strategy, SWOT and Corporate Finance Report Summary Ciber, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Orpea SA (ORP):企業の財務・戦略的SWOT分析
    Summary Orpea SA (Orpea) is a healthcare consulting company that offers clinical care services. The company provides services such as suite care clinic services, retirement homes, and mental hospital services, among others. Its mental hospital services include treatment of mood disorders, overuse sy …
  • Applied Genetic Technologies Corp (AGTC):製薬・医療:M&Aディール及び事業提携情報
    Summary Applied Genetic Technologies Corp (AGTC) is a pharmaceutical company that provides development of eye disease cures. The company develops treatments for patients that have diseases caused by broken genes. It offers products such as x-linked retinoschisis, achromatopsia, x-linked retinitis pi …
  • Intezyne Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Intezyne Inc (Intezyne) is a biotechnology company that develops product candidates for the treatment of various cancer tumors. The company offers anti-cancer agents and IVECT method to improve cancer therapy. It provides compounds that are cellular or molecularly targeted or have tumor-spec …
  • Beiersdorf AG:企業の戦略・SWOT・財務情報
    Beiersdorf AG - Strategy, SWOT and Corporate Finance Report Summary Beiersdorf AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Ansell Limited:企業の戦略・SWOT・財務分析
    Ansell Limited - Strategy, SWOT and Corporate Finance Report Summary Ansell Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Innate Immunotherapeutics Ltd (IIL):製薬・医療:M&Aディール及び事業提携情報
    Summary Innate Immunotherapeutics Ltd (Innate Immunotherapeutics), formerly Innate Therapeutics Ltd is a pharmaceutical company that develops therapeutic drugs for the treatment of cancer and infectious diseases. The company utilizes immunomodulator microparticle technology. It develops lead drug ca …
  • Pascal Biosciences Inc (PAS):製薬・医療:M&Aディール及び事業提携情報
    Summary Pascal Biosciences Inc (Pascal Biosciences), formerly BioMmune Technologies Inc is a biotechnology company that discovers and develops treatments in the field of immuno-oncology. The company develops targeted agents that enable the body's own immune system to recognize and attack cancers, in …
  • Moneygram International, Inc.:企業のM&A・事業提携・投資動向
    Moneygram International, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Moneygram International, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and …
  • iDD biotech SAS-製薬・医療分野:企業M&A・提携分析
    Summary iDD biotech SAS (iDD biotech) is a healthcare products provider that discovers and develops differentiated therapeutic antibodies. The company's products comprise pre-clinical stage therapeutic monoclonal antibodies and active drug discovery programs. It develops therapies for the treatment …
  • Allegion Plc:企業の戦略・SWOT・財務情報
    Allegion Plc - Strategy, SWOT and Corporate Finance Report Summary Allegion Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Children’s National Health System:医療機器:M&Aディール及び事業提携情報
    Summary Children’s National Health System (CNHS) formerly Children's National Medical Center, is a health care institution which offers pediatric care services. The institution offers pediatric emergency, trauma, neonatal acre, neurosurgery, endocrinology, metabolic diseases and respiratory disorder …
  • Annaly Capital Management Inc:企業の戦略・SWOT・財務情報
    Annaly Capital Management Inc - Strategy, SWOT and Corporate Finance Report Summary Annaly Capital Management Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • E.ON SE (EOAN)-エネルギー分野:企業M&A・提携分析
    Summary E.ON SE (E.ON), formerly E.ON AG, is an energy company that generates electricity, produces, stores, transports, and supplies gas and conducts trading, carbon sourcing, and electricity and gas distribution. It generates power from diverse fuel sources including wind, hydro, nuclear, coal, na …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆